STOCK TITAN

Royalty Pharma: Sandy Lamm LLC proposes $10.3M sale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Royalty Pharma plc (RPRX) has a notice of a proposed sale of 150,000 Class A ordinary shares by Sandy Lamm LLC, whose relationship to the issuer is listed as officer. The approximate sale date is November 16, 2026, and the shares have an aggregate market value of $10,278,750. Merrill Lynch is named as the broker. Sandy Lamm LLC acquired the shares from the issuer in a private transaction on June 16, 2020. The sale is made in connection with a selling plan dated August 7, 2026, intended to comply with Rule 10b5-1(c).

Class A ordinary shares proposed for sale 150,000 shares Approximate sale date November 16, 2026
Aggregate market value $10,278,750 Value of the 150,000 Class A ordinary shares proposed for sale
Class A ordinary shares outstanding 445,265,805 shares Outstanding share count shown in the securities information
Rule 10b5-1(c) regulatory
"intended to comply with Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
aggregate market value financial
"Aggregate Market Value"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RPRX shares does Sandy Lamm LLC plan to sell?

Sandy Lamm LLC proposes to sell 150,000 Class A ordinary shares, with an aggregate market value of $10,278,750. The approximate sale date is November 16, 2026, and Merrill Lynch is named as the broker.

Is Sandy Lamm LLC’s proposed RPRX sale tied to a Rule 10b5-1 plan?

Yes. The sale is made in connection with a selling plan dated August 7, 2026, which is intended to comply with Rule 10b5-1(c).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading